Delivering AI-powered pathology to drive insight in cancer diagnosis

Through the collaboration, the partners will advance the use of AI-enabled solutions to deliver new insights to pathologists for two of the most common cancer diagnoses. 

Driven by a growing base of evidence on the economic and clinical benefits of adoption, leading laboratories are increasingly looking to adopt AI in routine practice to optimise operations and improve patient care. In a Nature survey of pathologists, 75% expressed interest in using AI to facilitate workflow and quality improvements, and 80% expected to be using AI by 2028.

Powerful computational applications such as Visiopharm’s portfolio of breast and colon solutions have highlighted the role that AI could play in improving diagnosis. However, a key barrier to deriving the full value of AI is the laboratory’s ability to seamlessly integrate this diverse range of applications into routine operations. 

Proscia and Visiopharm have joined forces to deliver a unified solution that combines Visiopharm’s suite of CE-IVD clinical AI applications – including breast IHC markers, breast metastasis detection, and colon metastasis detection – with Proscia’s CE-IVD Concentriq Dx platform for image-based data and workflow management. Users of Concentriq Dx can now leverage the full suite of Visiopharm’s AI applications directly in the routine workflow, helping pathologists quantify the expression of biomarkers aiming to accelerate treatment decisions for patient care. This marks an expansion of the companies’ existing collaboration integrating AI-enabled solutions which have successfully driven breakthroughs in translational research and advance precision medicine for life sciences companies. 

Click here to learn more about how Visiopharm and Proscia are helping organisations to realise the full promise of their digital pathology data.